We are now forecasting that a larger majority of our current and future pre-filled syringe capacity coming online in fiscal 24 through fiscal 26 is expected to be booked soon in support of this exciting category of products, confirming our position as a leading CDMO in this space globally. Despite imposing measures to limit spending, Catalent has continued to advance capacity projects at its fully utilized drug product facility in Brussels, Belgium as a result rising GLP-1 demand, while plans are underway to accelerate investments in fill and finish facilities in Bloomington, Wisconsin and Anagni, Italy
Accessed 2/22/2022, Shi Q, Wang Y, Hao Q, et al
Average 15% body weight loss over 68 weeks at 2.4 mg (e.g., 30 lbs from 200 lbs starting weight)
Consistency across all seven days matters more than perfection on weekdays alone
However, no clinical trials have evaluated this combination, so added benefit is unclear
Understanding tirzepatide refrigeration requirements and what happens when tirzepatide gets warm ensures you maintain the purity you paid for
